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Psoroptes ovis (Hering, 1858) is an astigmatid mite that causes the highly 
contagious and debilitating disease known as sheep scab. This ectoparasitic 
infection has high economic and welfare costs for British sheep farming. 
The condition is augmented through a host hyper-immune response that instigates 
the production of an exudate, antigenic serum containing immunoglobulins in 
response to the mite recombinant protein, Pso o 2. This reaction causes intense 
pruritus and epidermal inflammation, which rapidly leads to severe deterioration in 
host condition. The most commonly used therapeutic treatment is topically or 
intramuscularly administered macrocylic lactones (MLs). Over the past decade 
there have been widespread reports of scab outbreaks that do not appear to 
respond to this group of compounds. A study by Doherty et al. (2018) was the first 
to demonstrate evidence of P. ovis resistance to the ML, moxidectin, in non-
responding populations, through a formulated bioassay. The data described in the 
present study supports the preceding evidence of moxidectin resistance in these 
non-responding populations, whilst also indicating that there are varying levels of 
intraspecific resistance to all three commonly used ML treatment compounds: 
ivermectin, doramectin and moxidectin. Outbreak samples that did not show 
evidence of resistance (despite being secondary outbreaks) and inviable samples 
received due to storage or transport method, highlights the widespread insufficient 
knowledge and understanding of P. ovis, its control and management, within the 
agricultural community. This further demonstrates the importance of strong 
biosecurity and stringent monitoring of regional flock health, necessary to maintain 
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CHAPTER 1  
INTRODUCTION 
 
1.1 THE BIOLOGY OF PSOROPTES OVIS AND CLINICAL INFECTION 
1.1.1 Classification and taxonomy 
The non-burrowing arthropod mite, Psoroptes ovis (Hering, 1838), is an obligate 
ectoparasite belonging to the family Psoroptidae (Order Astigmata). Psoroptes 
mites are seen in all seasons and can infect a wide variety of mammalian hosts 
including cattle, rabbits, various camelids and sheep (Shilston, 1915; Downing, 
1936). P. ovis are traditionally given different species names depending on the 
primary host species they infect (Wall and Kolbe, 2005). However, molecular 
studies comparing and contrasting the second mitochondrial internal transcribed 
spacer (ITS-2) of different P. ovis variants, reveal no genetic differentiation between 
Psoroptes mites that infect different host species (Pegler et al., 2005). Despite this, 
there are distinct phenotypic differences between different host-derived P. ovis and 
pathological differences in host responses to infection. Psoroptes infection can be 
separated into two types: infection resulting in bodily mange and infection resulting 
in acute otoacariasis (Bates, 1999). It has been suggested that ear forms may 
represent the ancestral interaction between mites and wild host with the more 
pathogenic body-form of infection being associated with more susceptible 
domesticated sheep (Pegler et al., 2005).  
Despite the variations in nomenclature, the name Psoroptes ovis is regarded as 
having taxonomic priority within the genus, as this was the nominal designation 
given when first described by Hering (Hering, 1838; Wall and Kolbe, 2005). The mite 
is the causative agent of Psoroptic acariasis or mange- the clinical disease 
colloquially known as ‘Sheep Scab’ (Shilston, 1915; Tarry, 1974; Lewis, 1997; Bates, 
1999).  Sheep scab is considered to be the most important ovine ectoparasite 
infection in Great Britain and many other countries, due to the significant economic 
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and welfare impacts to livestock and agriculture (Kirkwood and Quick, 1982; 
O’Brien, 1999; van den Broek and Huntley, 2003). 
Records of the disease date back to pre-180BC, in the writings of classical authors 
such as Cato and Virgil alongside biblical parallels within the Old Testament 
(Kirkwood, 1986), however, the causal agent was not identified until recognised as 
a mite by Walz in 1809.  
In the United Kingdom, Sheep Scab has been of high national importance, 
predominantly due to its economical and welfare impacts, seen throughout the 
period of British Agricultural Revolutions. Changes in control strategy and 
nationwide policy during the 19th century, particularly with the deregulation of 
dipping, have resulted in a higher disease prevalence across the British Isles 
(Nieuwhof and Bishop, 2005).  
 
1.1.2 Morphology and Life History  




The characteristic distinguishing features of Psoroptes ovis are its pointed 
mouthparts and three-jointed pretarsi bearing pulvilli (Wright and Deloach, 1980). 
The body profile is oval and legs protrude from the body margin. Adult females 
have jointed pre-tarsi on the first, second and fourth pairs of legs with long setae on 
the third. Conversely, adult males (Fig. 1.1) are smaller and distinguished by 
coupled posterior lobes and posterior copulatory suckers (Sanders et al., 2000). The 
part of the body incorporating the feeding organs is called the gnathosoma and the 
posterior part of the body is the opisthosoma.  
The lengths of the posterior opisthosomal setae of adult males were believed to be 
the distinguishing feature for P. ovis host-derived species (Sweatman, 1958), 
however these measurements may vary over the course of infection, with setae 
length inversely correlated to infection lesion age and so making this character 
taxonomically unreliable (Wright et al., 1984).  
The early observations of the parasite’s life-history were undertaken by Gerlach in 
1857 and debate over the pattern and rate of development continued throughout 
the early literature with highly divergent observations (Shilston, 1915). In-depth 
analysis of these early population observations and assessment of the P. ovis life-
cycle were undertaken in South Africa in the early 20th century using confined 
populations on living sheep (Downing, 1936).  This showed that P. ovis undergoes 
five life-cycle stages as follows: egg, hexapod larva, two octopod nymphal stages, 
(designated as the protonymph and tritonymph) and the octopod adult.  
At the larval stage, both sexes have 3 pairs of legs and moult in to protonymphs 
after 2 days. Female nymphs can be distinguished from males by size and the 
presence of dorsoposterior tubercles, however, distinguishing between nymphal 
stages depends on the number of metapodosomal setae and location of cuticular 
pits (Sanders et al., 2000). In astigmatid mite species, the protonymph moults 
directly into the tritonymph, omitting the deutonymphal instar seen in other mite 
species e.g- the spider mite, Tetranychus urticae (Gotoh, 1986; Sanders et al., 
2000). Female adults are substantially larger than males (Sweatman, 1958). Males 
develop posterior copulatory tubercles (Fig. 1.1). Mature males form pairings with 
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female tritonymphs and copulation occurs when the attached nymph moults into 
the adult stage (Shilston, 1916; Downing, 1936).  
All developmental stages occur on the host and key morphological features 
distinguish each stage of the life-cycle, which can be completed in approximately 
10-19 days, with each life cycle stage taking at least 2 days (Downing, 1936;
Sweatman, 1958; Sanders et al., 2000). However, the exact rates of development
are highly dependent on temperature and humidity. For example, Shilston (1915)
observed that there is a period of two to nine days between egg oviposition and
hatching, dependent on the egg’s proximity to the host epidermis. Female mites
can live for 11-42 days, depending on the conditions of temperature, humidity and
food availability. In a favourable environment, females can deposit up to 90 eggs
during one life-cycle (Stockman and Berry, 1913).
Environmental transmission may be important in the epidemiology of sheep scab, 
so off host survival is an important factor.  As mentioned earlier, studies have 
shown that off-host survival is highly dependent on temperature and humidity, 
therefore survival may be extremely variable (Hertwig, 1835; Salmon and Stiles, 
1903; Bedford, 1915; Dill, 1920; Tarry, 1974; Kirkwood, 1986). Mites can remain 
infectious off host for a maximum of 15 days (O’Brien et al., 1994).  
Although outbreaks of P. ovis can be seen year-round in the United Kingdom, it has 
been observed consistently that infection incidence peaks during the winter 
months (Shilston, 1915; Downing, 1936).  A Leslie matrix model was used to predict 
that a population of Psoroptes mites on a sheep is likely to grow at a rate of about 
11% daily with the population doubling every 6.3 days. Mite populations increase 
exponentially after an initial period of instability once infections have established 
(Wall et al., 1999). Hence, P. ovis infection can lead to rapid disease progression. 
1.1.3 Pathology 
Although it is a non-burrowing mite, P. ovis causes chronic dermatitis and severe 
pruritus. Scanning electron microscopy shows that Psoroptes have mouthparts 
adapted for epidermal abrasion and liquid feeding (Mathieson and Lehane, 2002), 
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but not, as was originally thought, for piercing through the epidermis (Downing, 
1936). Psoroptes mouthparts do not appear to penetrate beyond the outermost 
layer of the host epidermis, the stratum corneum (Sinclair and Kirkwood, 1983). 
Mites feed superficially on a liquid emulsion of lymph and bacteria produced at the 
host epidermis layer (Rafferty and Gray, 1987; Synge et al., 1995) ingested through 
their pharynx and oesophagus. The pharynx is lined with a cuticle heavily composed 
of sclerotin and accompanied by three dilator muscles thought to draw liquid 
through the roof of the gnathosoma. The structure of the foregut is similar to other 
species of Acari except for a pharyngo-oesophageal valve which is not a general 
feature of most Acari, however is found in some related astigmatid mites such as 
the house dust mite, Dermatophagoides farinae (Brody et al., 1972).  
Infestation may be localised and often subclinical, particularly in the early stages of 
infection. In localised infection mites commonly aggregate on the flanks, back or 
legs of the host (Sargison, 1995; Bates, 1997). In the field, natural subclinical 
infections can endure for 2-8 months, followed by an exponential population 
growth phase in which clinical signs advance (Sargison, 1995; Bates, 1997). When 
infection is generalised, mites may extend across the entire body.  
The clinical pathology of a P. ovis infection is the result of a hyper-immune response 
by the host. When the mites establish themselves on the host, guanine-rich faecal 
matter and antigenic salivary material is deposited on the skin, causing an 
immediate immune reaction. Homologues of the house dust mite allergen proteins 
have been generated from P. ovis cDNA, which react with immunoglobulin G and 
other serum antibodies to elicit the epidermal inflammatory effects in sheep (Bates, 
1997; Lewis, 1997).  
Microflora in the parasite midgut and antigenic material from bacterial digestion 
may influence the severity of host-response. The behavioural reactions of sheep to 
the infection arise from irritation and inflammation. Rubbing causes skin abrasion 
and epidermal tears allowing for subcutaneous microbial infiltration and secondary 
infection. Serratia marcescens has been linked with mite infection and is known to 
cause disease and septicaemia in mammals (Mathieson and Lehane, 1996). 
Increases in P. ovis specific IgG and IgE have been detected in sheep at 2-3 and 4-5 
13 
weeks after an initial infection. Subsequently, infection then results in rapid 
anamnestic IgE production, but not IgG. Pathology and immune-response 
progression may vary between sheep breeds (Fisher et al., 1998; Smith et al., 2001).  
The disease is highly contagious with transmission resulting from direct contact 
between animals, or indirectly from handling equipment or shared environmental 
components. Due to the high rate of population growth, infection with small 
numbers of ovigerous female P. ovis, can lead to a full clinical infestation in 6 to 8 
weeks (Babcock and Black, 1933), although progression of the clinical disease varies 
on whether or not it is a primary infection or whether the sheep has been infected 
beforehand. In primary infections there is an initial “lag” phase followed by a fast-
expanding “growth” phase with an increase in abundance and size of scab lesions. 
Secondary infection growth has a prolonged lag phase and a less aggressive growth 
phase, as a result of the immune system protection of the previously infected sheep 
(Bates, 2000).  
 
1.1.4 Clinical signs and diagnosis  
Clinical signs of sheep scab vary over the course of an infection and are dependent 
upon environmental factors. Typical signs include rapid weight loss through 
preoccupation with, and agitation of, clinical symptoms coupled with protein loss 
through exuding immunogenic serum. Other responsive signs include tongue 
protrusion, lip smacking, rubbing and nibbling at the fleece; which can result in hair 
loss, epidermal damage, epileptiform fits and self-trauma (Fig. 1.2).  Following this, 
possible fatalities arise from secondary infections, pneumonia and severe 
dehydration (Tarry, 1974; Kirkwood, 1980; Bates, 1997; Bygrave et al., 1993). 
Lesions and cutaneous inflammation are generated with progressing dermatitis and 
self-trauma reveals ulcers and epidermal abrasion. Lesions extend to 
aforementioned areas of common mite localisation and an antigenic serum exudate 
is produced alongside pustule discharge, staining the wool yellow as the exudate 





Fig. 1.2. Veterinarian taking scrape from Psoroptes ovis mite infected area on an 
ewe (Wiltshire, 2018, © C. Sturgess-Osborne). 
Sargison et al. (2005) has shown that when a pregnant ewe contracts sheep scab, a 
loss of condition is positively correlated with scab severity. Lambs of severely 
infected ewes were seen to have a lower birth weight than those mildly infected or 
free from Psoroptes. Pregnancy also causes other complications during scab 
infection. The pharmacokinetic parameters of treatments can change during 
pregnancy. A substantial decrease in the half-life of moxidectin elimination was 
found in pregnant ewes, suggesting that treatment longevity is reduced during 
pregnancy (Pérez et al., 2014). 
In bovine infection, P. ovis (syn P. bovis) extends fully across a lesion, whereas in 
sheep they aggregate at the edge between the lesion and normal skin. This is likely 
due to the uninhabitable local environment created by the fast-drying serum 
exudates at the lesion on sheep, which is not found in cattle infection. In cattle 
scab, lesions remain moist, creating an optimal humidity for mites (Kirkwood, 
1986). 
 
1.1.5 Epidemiology and distribution  
Sheep scab epidemiology in 21st century Britain is not uniform, with higher 
concentrations of distribution found in Scotland, Northern England and Wales 
(Bisdorff et al., 2006). A more recent control survey found that 60% of the sheep 
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farming community did not use prophylaxis treatment. This is suspected to be on 
economic and efficiency grounds and due to confusion within the farming 
community on effective treatment strategy, as well as avoiding treatment 
interruption of seasonal husbandry practices. Application of acaricidal compounds 
during the summer period is convenient in relation to other on-farm activities such 
as shearing, prevention of other treatment-susceptible livestock ectoparasites and 
treating around the prenatal periods that prevent dipping in winter. The ineffective 
treatment timing in respect to sheep scab seasonality can result in the re-
emergence of scab, lowering confidence in prophylaxis within the British farming 
community (Bisdorff and Wall, 2008). 
It is considered that upland and lowland areas in Britain need discrete control 
systems, as differences in husbandry practice and environmental factors lend to 
distinct variations in transmission risks and disease spread between flocks (Nixon et 
al., 2017). Observations across the literature clearly demonstrate that population 
dynamics and epidemiology are influenced by a multitude of interacting factors, 
both intrinsic within the microclimate of the host-parasite interaction coupled with 
external environmental contributions (Bates, 1997; O’Brien, 1999). The complexity 
of these dynamic systems causes the ongoing difficulty in effective control of the 
disease. 
 
1.1.6 Economic and veterinary importance  
There are approximately 35 million agricultural sheep in the UK, equating to £1,197 
million towards agricultural-based income in meat production alone (UK 
Government Statistics, 2017). A calculated estimate for the annual cost of P. ovis to 
the UK was £8.3 million (Nieuwhof and Bishop, 2005). However, this calculation did 
not take into account the monetary losses from labour, transmission impacts- such 
as movement restrictions limiting land use and subclinical disease impacting 
productivity in sheep and other susceptible mammals. Therefore, the cost is likely a 
lot higher, even before incorporating an economic inflation adjustment for the 
current year (Nixon et al., 2017). Production loss is a large component around the 
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significant economic impacts of P. ovis.  Psoroptic mange and other prevalent ovine 
ectoparasite diseases, such as cutaneous myiasis, have high welfare impacts and 
risk of mortality on sheep of all ages (Scott et al., 2007).  
 
1.2 THE HISTORY AND CONTROL OF SHEEP SCAB IN GREAT BRITAIN 
1.2.1 History of psoroptic mange control 
Records of scab prevention date back as far as 180 BC. Cato the Elder advised that 
after shearing, sheep should be treated with a mixture of strained olive oil lees, 
water that had soaked (“steeped”) plants of the genus Lupinus and dregs of 
barrelled wine. His writings then instruct that one should let the sheep “sweat 
profusely for 2-3 days” followed by dipping in saltwater, which he claimed would 
prevent future scab and tick infection (Cato, 180BC). Similar treatment methods 
using lard and mercury were used during the middle-ages. A virulent outbreak of 
scab resulting major economic losses was recorded in Belgium (then Flanders) in 
1275 (Stephenson, 1988).  This outbreak was believed to have been imported from 
Britain, due to the country’s reliance on imported English sheep wool. In the UK, 
confirmed records of scab were recorded in 1807, when there were 2573 
outbreaks, rising to 3536 in 1895 (Kirkwood, 1986).  
It is thought that the earliest legislation imposed to control sheep scab in Britain 
dates from AD 949, when King Hywell Dda of Wales forbade trade of infected flocks 
between November and April (Kirkwood, 1986).The first official British law 
regulating scab control was a House of Lords amendment passed in 1798, 
preventing the grazing of animals on pastures that harboured scab infected sheep 
(Journals of the House of Commons, 1798; Fig. 1.3).  
The first commercially available dips in Great Britain, based on arsenic, became 
available in the mid-19th century. After a period of experimenting between 1843-
1852 with arsenic and sulphur, William Cooper formulated ‘Cooper’s Dip’ (Downing, 
1936). In the years previous to this, scab was inadequately managed with 
treatments containing soot, goose-grease, tobacco and flour of brimstone (Ellis, 
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1749). Various other compounds were trialled over the 19th century using tar, 
rotenone and creosote.  
Fig. 1.3.  Journals of the House of Commons agreement to Lords Amendment on 
the depasturing act in England 1798 (adapted for clarity). 
Initial statutory control was achieved through the Sheep Scab Order of 1898, which 
required authorities to liaise with veterinary surgeons for diagnosis. Case 
prevalence dropped from 2514 in 1898 to 1379 by 1901, however the extent of 
which this was due to the early Scab Order has been debated (Page, 1969). 
Compulsory single dipping was introduced in 1905 and a second Scab Order was 
imposed in 1907 (Board of Agriculture and Fisheries, 1906; Downing, 1936) 
18 
regulating the use of a new dip formulation with lime sulphur, arsenic and phenols 
(Salmon and Stiles, 1900; Kirkwood, 1985).  
Double dipping was introduced during the early 20th Century, 1914. In 1920, it was 
understood that no available single dip ensured egg mortality, thus a second dip 
was needed to ensure that newly hatched mites were killed. Local authorities were 
also given the power to impose single, double or triple annual dipping in their 
specific regions. A 1928 act limited treatment use to ministry approved compounds 
only, as well as demanding euthanasia of infected individuals and enforcing 
movement and isolation restrictions on infected flocks (Downing, 1936; Spence, 
1951). 
Pre-1947 treatments had low persistence until the development of organochlorine 
compounds which gave high levels of mortality and residual protection for up to 3 
months (O’Brien, 1999). In 1948, the introduction of gamma-
hexachlorocyclohexane (GHCH [syn lindane or γ-HCCH]) and compulsory dipping 
eventually resulted in the eradication of Sheep Scab in 1952. A re-emergence 
occurred in 1972, which is believed to be the result of import and initial infection 
misidentification during the transport of infected sheep from Ireland. The outbreak 
was eventually identified on January 1st, 1973 in Lancashire, by which time 
considerable dispersal had already occurred from the initial point of introduction 
(Kirkwood, 1985).  
In 1972 lindane (Gamma H-CH) was the only evidence-backed treatment available 
(Tarry, 1974). Environmental and health concerns, plus evidence of scab mites 
developing resistance to lindane (Rosa and Lukovich, 1962), led to the introduction 
and use of a generation of less persistent synthetic pyrethroids (high cis-
cypermethrin and flumethrin) and organophosphate, with diazinon and 
propetamphos being licensed for Sheep Scab in 1981 (Tarry, 1974; Bates, 2004).  
Propetamphos was considered to be a particularly effective compound as it was 
also administered for blowfly and lice management (Kirkwood and Quick, 1981; 
Kirkwood and Quick, 1982).  
Dip-formulae containing lindane and other organochlorines were voluntarily 
withdrawn in 1984 primarily due to risks of residual meat contamination although a 
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wide range of environmental issues are now known to result from their use 
(Henderson, D., 1991; Kunz and Kemp, 1994). Synthetic pyrethroid (SPs) insecticides 
were banned in the 1990s because of environmental concerns.  
Currently, only two classes of acaricidal compound are still licensed for treatment of 
P. ovis: diazinon organophosphate dip (OPs), and injectable macrocyclic lactones 
(MLs) (Lewis, 1997). OP insecticides have phosphate radicals which act as carboxylic 
esterase inhibitors through phosphorylating enzymes at the active site. 
Toxicological impacts of OPs are driven by the inhibition of acetylcholinesterase 
within the nervous system. Case studies throughout the 1970s showed that the 
resulting excess of acetyl-choline, at cholinergic synapses, disabled somatic nerve 
transmission, sparing only nerves of the adrenergic nervous system (synapses of the 
neurotransmitters epinephrine and noradrenaline) (Ahlquist, 1948; Namba et al., 
1971).  Considerable concerns have been raised over the human health impacts of 
exposure to OPs.  A study showed that the OP insecticide used in scab treatment, 
diazinon, acted as an anticholinesterase in healthy human erythrocytes (Namba et 
al., 1971). This mechanism was not responsible for the neurotoxicity of OPs seen in 
humans. Neuropathic abnormalities were thought to be a result of esterase, over 
cholinesterase, inhibition from the OP containing compound- triorthocresyl 
phosphate (Cavanagh et al., 1961). Additional studies of the mechanisms behind 
the interaction of OP compounds with the neurodevelopmental gene pathways and 
cell apoptosis, may reveal the mechanism of action behind correlated user 
neurotoxicity (Slotkin and Seidler, 2012). Some laboratory studies suggest OPs 
cause changes of expression in lipid-based enzymatic pathways, serine hydrolases 
and cAMP expression. Several systems in the brain are modulated by lipases 
sensitive to oraganophosphate exposure. For example, monoacylglycerol lipase and 
the fatty acid amide hydrolase, regulate neural endocannabinoid levels (a group of 
endogenous neurotransmitters involved in mobility, memory and pain 
mechanisms). OP exposure has been found to inhibit these enzymes in mice, 
resulting in augmented endocannabinoid concentration in the brain (Casida et al., 
2008). Neurotrophic abnormalities such as defective axonal transport and 
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alterations in the intensity and timing of neurotransmitter signalling, lead to 
behavioural and physiological defects in people working with OPs (Slotkin, 2004).  
MLs now available for scab management and prophylaxis include the avermectins 
(ivermectin and doramectin) and the milbemycin, moxidectin. They are the highest 
selling anthelmintics globally. MLs are endectocides and can kill both endo- and 
ectoparasites (Shoop et al., 1995). They are also used for nematode control in 
horticulture and the control of river blindness (onchocerciasis) in humans (Omura 
and Crump, 2004). These chemically related compounds are derived from 
fermentation products of Actinomycetales bacteria, Streptomyces. Ivermectin and 
doramectin are derived from the bacterium Streptomyces avermitilis; moxidectin 
was originally derived from S. hygroscopicus and then from S. cyaneogriseus from 
1983 (Chiu et al., 1987). Within nematode and arthropod nervous systems, the 
primary mode of action behind all MLs is to modulate the action of chloride ion 
channels. All three of the compounds used for sheep scab treatment are 16-
membered lactone compounds, with potent insecticidal and anthelmintic 
properties. The milbemycin, moxidectin, differs from the other avermectins as it is 
unglycosylated and protonated, thus unsubstituted and lacking a bisoleandrosyloxy 
(disaccharide) substituent at C13 (Campbell et al., 1983). Doramectin is a 
synthetically-modified avermectin, with a cyclohexyl, C6H11, group at C25 and having 
a greater active period and plasma half-life than ivermectin (Shoop et al., 1994; 
Banks et al., 2000; Voyvoda et al., 2005). Homogenous structural components allow 
for all to bind glutamate-gated chloride channel receptors (Burg et al., 1979; 
Egerton et al., 1979; Campbell et al., 1983; Campbell, 1989; Prichard et al., 2012; 
Fig.1.4).  
ML pharmacophores have a low affinity for mammalian ligand-gated chloride 
channels and glutamate-gated chloride channels are only found in protostome 
invertebrates, thus MLs do not readily cross the blood-brain barrier of mammals. 
Therefore, the use of these compounds is considered to have a high margin of 
mammalian safety and they do not have negative effects in the mammalian 
peripheral nervous systems at standard dosage concentrations (Slimko et al., 2002; 
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Wolstenholme, 2012). The MLs act as substrates for permeability glycoproteins (P-
gp), being ATP-dependent efflux membrane pumps.  
Ivermectin was the first ML developed for use in veterinary treatment. Its 
vermicidal effects are exerted through selectively binding glutamate-gated chloride 
channels in invertebrates. In the compound class, other ML compounds can cause 
the potentiation of bind/release mechanisms of the neurotransmitter, gamma-
aminobutyric acid (GABA). The increase in permeability of chloride ions when 
binding to glutamate-gated Cl- channels causes an influx of chloride ions resulting in 
hyperpolarisation of nerve cells and consequential paralysis and death of the 
parasite- as schematically represented in Appendix A (Egerton et al., 1979; 
Campbell et al., 1984; Cully et al 1996; Slimko et al., 2002; Lanusse et al., 2009) .  
In 1983, scab incidence was very low at between 10 and 100 outbreaks per year 
(Page, 1969; Loxam, 1974; Kirkwood, 1986). However, the last remaining cases of 
scab could not be eradicated; it is thought that this was due in part to the lower 
residual activity of OPs and SPs, though farmer non-compliance may also have been 
important.  Given that the vast majority of sheep dipped each year in the UK did not 
have scab and that dipping was both expensive and environmentally damaging, the 
government decided to abandon attempts at national eradication; scab was 
deregulated in 1992 and national compulsory dipping was abandoned. Following 
this, the number of scab outbreaks rose dramatically and there are now thought to 
be approximately 5,000-10,000 outbreaks each year (Bisdorff et al., 2006; Nixon et 
al., 2017).  
One of the economic factors contributing to the high cost of P. ovis is the economic 
loss in animal product-based food sales. Meat withdrawal is due to the presence of 
treatment residues in blood plasma after treatment. The plasma of cattle injected 
with moxidectin was assessed against the plasma concentration in their calves 
which had not been treated. Blood was taken from cows and their calves at 
intervals over 120 days and centrifuged for analysis by chromatography. It was 
found that circa 5% of the moxidectin, which had been administered at standard 
dosage recommendations, had been transferred to the calf via the mother’s milk 
(Alvierie et al., 1996). The meat withdrawal periods of the ML products used in the 
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current study are as follows: subcutaneous injection of 2% Long-Action Cydectin 
(moxidectin) is administered at the base of the sheep ear and meat withdrawal 
period after treatment is 104 days. For Dectomax 10mg/ml (doramectin) which is 
administered as an intramuscular injection, the withdrawal is 70 days, and this is 
the only licensed treatment that treats scab in a single injection. Dectomax is also a 
popular treatment in the farming community because it treats gastrointestinal 
worms and lung worm alongside scab in sheep and cattle. Alternatively, Oramec 
(ivermectin) is given via oral drench and meat withdrawal is only 6 days. However, 
neither ivermectin nor doramectin provide any long-term length of protection, 
whilst Cydectin (moxidectin) gives 60 days residual protection against P. ovis re-
infection (pers comm. Zoetis, product technical team, 2017).  
Ivermectin is highly life-stage specific and does not target as wide a range of species 
as the other avermectins (Campbell and Benz, 1984). These differences in the 
treatment are considered when farmers and veterinarians are making decisions on 
treating a new scab outbreak. OP dips are the most economical control method for 
sheep scab. Despite this, a survey of 966 farmers located across the UK found that 
the majority, an average of 56.3%, used injectable insecticides to treat scab whilst 
only 27.5% used a dip and 16.3% combined both (Bisdorff and Wall, 2008). While 
the injectable MLs (ivermectin, doramectin and moxidectin) and the full-immersion 
plunge-dipping compound, diazinon, are the only compounds licensed for the 
treatment of sheep scab, a recent survey in Wales showed that there is 
considerable confusion in the use of appropriate products with numerous cases 
observed in which farmers used inappropriate products in an attempt to treat scab 
(Chivers et al., 2018).   
 
1.3 DEVELOPMENT OF RESISTANCE 
1.3.1 Records of resistant Psoroptes ovis  
Where the mass-scale administration of any compounds is used for parasite 
control, particularly where there is limited variation or rotation in the treatments 
available, selection for resistance is expected to be almost inevitable (Bates, 1998). 
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Accordingly, drug-resistance in a wide range of ovine parasites has been reported 
(Synge et al., 1995). The first report of pyrethroid-resistant scab was in 1995. 
Resistance may have been facilitated by asymptomatic scab cases being exposed to 
low dose concentrations when pyrethroids were used to treat other ectoparasites. 
It was predicted that resistance of ovine parasites to avermectins and milbemycins 
could develop due to the incomplete treatment and low-level exposure in 
subclinical scab populations (Coles, 1998). The use of MLs to manage scab might 
also facilitate the section for resistance in nematode parasites. Resistance in ovine 
parasites has been an increasingly common observation over the past two decades, 
for example with resistance seen in the nematode Teladosagia circumcincta to 
benzimidazoles, tetrahydropyrimidines, imidazothiazoles and macrocyclic lactones 
(Sargison et al., 2003).  
 
1.3.2 Recent emergence of persistent scab outbreaks 
A recent study identified resistance to moxidectin in British sheep flocks (Doherty et 
al., 2018). Failure of ML treatment for Psoroptes is not only limited to sheep scab 
outbreaks. A trial of injectable ivermectin to treat Psoroptes in Belgian blue cattle 
(described as Psoroptes bovis), failed to cure over 50% of hosts (Lekimme et al., 
2010) leading to a presumption that the mites were resistant.  Nevertheless, other 
studies have shown differences in efficacy between various products containing 
ivermectin (Genchi et al., 2008) and the trial by Lekimme et al., (2010) was of 
limited size and did not have appropriate controls.  
The study conducted by Doherty et al. (2018) was carried out after consistent 
reports of outbreaks that were non-responsive to treatment in areas of high sheep 
scab prevalence across Britain. The results demonstrated that there are outbreaks 
of P. ovis that are resistant to moxidectin within the UK. The authors suggested that 
given the similar pharmacological interactions between the different MLs and 
substrates at chloride channels, these resistance populations were likely to show 
tolerance to other established ML treatments within this class, e.g. ivermectin and 
doramectin based compounds. As described (See Chapter 1.2.1), MLs act as 
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substrates for permeability glycoproteins (P-gp), being ATP-dependent efflux 
membrane pumps at chloride channel receptors, shown schematically in Appendix 
A (Fig. 1.5). 
All three MLs currently used to treat sheep scab (class avermectin: ivermectin and 
doramectin and class milbemycin: moxidectin) have superimposable structural ML 
groups (Shoop et al. 1995; Fig. 1.4). It has been observed that ivermectin-resistant 
worms present lower susceptibility to moxidectin treatment (Conder et al,. 1993). 
Further study on this phenomenon showed that Haemonchus contortus selected for 
moxidectin resistance, also presented lower susceptibility to ivermectin treatment 
(Molento et al., 1999). Whilst the mechanism of resistance in sheep scab is not yet 
fully understood, the results of the (2018) Doherty et al. study showing P. ovis 
resistance to moxidectin in the UK, commands investigation into cross resistance to 
the other MLs in non-responding P. ovis outbreak populations.  
 
Fig. 1.4. Superimposition of avermectin and milbemycin molecules (from Shoop et 
al., 1995). 
By determining a shared attribute in the biochemical pathway of the different ML 
treatment interactions within the ovine parasite system, mechanisms underlying 
resistance may be understood. For example, over-expression of P-glycoproteins 
which mirror the function of a membrane efflux pump is thought to be partially 





strains (Molento et al., 1999). Therefore, investigation into cross- resistance in P. 
ovis is paramount in understanding the mechanism of resistant strains.  
 
Fig. 1.5. Interaction of ivermectin (IVM) with a glutamate-gated chloride channel 
(GluCl) as proposed by Hibbs and Gouaux (2011), showing moxidectin (MOX; 
maroon) superimposed over IVM (black). Note that while some of the interaction 
sites are shared in common between MOX and IVM (O10, O13, C18, C35 and C48), 
other interaction sites of IVM with the GluCl are absent (C32, C33; both forming 
van der Waal (VDW) interactions with the GluCl in the case of IVM) due to the 
absence of any saccharide group in MOX, are blocked/altered (O14; H-bond in the 
case of IVM) by the C23 methoxime group of MOX. 
The sites where interactions will be different for MOX compared with IVM are 
highlighted by a solid red circle. The 25-dimethly-butyl of MOX may also affect 
interaction with the GluCl (dashed red circle). IVM is a mixture of C25 ethyl (B1a; 
∼10%) and C25 methyl (B1b; ∼90%). Against nematodes the B1b component is 
usually more potent than the B1a component, showing that the change from 
methyl to ethyl at this position affects potency. Thus, it is likely that the 25-
dimethyl-butyl group of MOX will also affect the interaction with a GluCl. from 
Prichard, R. et al. (2012). 
1.3.3 Future control development 
Future use of the current acaricidal compounds is highly uncertain, given the effects 
of exposure on treatment operators and the environment described, coupled with 
the evidence of parasite resistance. Continued cooperation and education between 
veterinary surgeries and farmers to employ strict biosecurity in flock handling and 
movement is the first stage in scab control. However, management by biosecurity 
alone is unlikely to be practical. Therefore, the development of novel biological and 
chemical control methods has received much attention from the research 
community over the past two decades in the aim of finding a working and 
sustainable control method.  Proposed alternative biological treatments include 
selective breeding for genetic resistance in sheep breeds showing low susceptibility, 
entomopathogenic fungi (Abolins et al., 2007), essential oils (Perrucci et al., 1995) 
as well as genetically modifying microorganisms that exhibit commensal 
relationships with Psoroptes, such as Bacillus thuringiensis, to produce toxins that 
are fatal for the parasite (Smith et al., 2001). However, to date none of these 
approaches has been sufficiently effective to lead to commercial development. 
Finding more effective, higher welfare and economical control methods for scab is 
important for future long-term management (Dunn et al., 2016).  
Development of an effective vaccination would provide many economic and safety 
benefits. Presently, attempts at creating a vaccine have only provided partial 
protection, reducing mite abundance and slowing lesion growth by >65% in re-
infections. Three vaccine antibody trials were tested by Smith and Pettit (2004) 
using soluble P. ovis extracts, made through the homogenisation of frozen mite 
material in a phosphate saline buffer. During trials they found that even natural 
innate resistance to infection in sheep was only temporarily protective. The 
practicality of developing a vaccine is also extremely difficult and expensive as P. 






1.4 Aims and Objectives 
Loss of drug effectiveness on parasite organisms is considered control failure. 
Studying field resistance can act as an important tool to establish biochemical 
action sites of resistance mechanisms.  Field resistance studies on an organism are 
an essential complement to laboratory molecular studies. In part, this is due to 
factors in laboratory studies that are not reflected in the field and the need for both 
to discover, understand and target biological sites that confer resistance within 
parasite physiology (Sangster et al., 2006). For example, resistance drift is seen 
within laboratory culture for ivermectin sensitive H. contortus which, as discussed 
(See Chapter 1.3.2), has been an important research organism for understanding 
the genomics of ivermectin resistance in ovine parasitic helminths (Gill & Lacey, 
1998).  
In light of the recent reports of P. ovis outbreaks not responding to ML treatment 
and the confirmation of moxidectin resistant Psoroptes organisms in the UK; this 
study aimed to determine whether outbreak populations of P. ovis that appeared 
unresponsive to treatment with moxidectin-based compounds, were also resistant 
or tolerant to the other compounds in this class. The response of seemingly tolerant 
P. ovis outbreaks to the milbemycin, moxidectin was explored, alongside responses 
to the macrocyclic lactones ivermectin and doramectin. The findings will identify if 
there is resistance to all three licensed ML-based compounds used to treat P. ovis in 
the UK. Therefore, indicating any necessary areas of research emphasis needed for 
the intervention and development of new control initiatives against the possible 




SHEEP SCAB RESISTANCE IN GREAT BRITAIN 
2.1 INTRODUCTION 
The fact that resistance has been reported in Psoroptes ovis to the milbemycin, 
moxidectin (Doherty et al., 2018), while of concern, does not necessarily mean that 
resistance to the other macrocyclic lactones is inevitable. Macrocyclic lactones have 
different pharmacological profiles in different mammalian hosts when infected with 
P. ovis. For example, the oral bioavailability of moxidectin is almost 3 times lower in 
goat species and it has a 2.3 times shorter half-life in plasma than when 
administered to sheep breeds (Steel, 1993; Baynes et al., 2000). Moxidectin is also 
almost 100 times more lipophillic than ivermectin. The aqueous compound formula 
of moxidectin is more readily absorbed into the bloodstream than its oil-based ML 
counterparts. Seven days after subcutaneous injection, moxidectin has a 16:7 fat to 
liver storage ratio opposed to that of ivermectin which is 1:7 (Hayes, 1994). 
Moxidectin is known to transfer from fat into the liver for up to 28 days post-oral 
treatment. Sheep show a more gradual increase in moxidectin blood concentration 
over time than cattle which is suspected to be due to a slower turnover of lipids 
seen in sheep (Afzal et al., 1994; Zulalian et al., 1994). Hence, these known 
pharmacological differences may result in difference in their effect on mite 
populations and so cross-resistance cannot be simply assumed.
2.2.  MATERIALS AND METHODS 
2.2.1- Origin of mites 
In this study, samples of naïve control populations of P. ovis mites were obtained 
from the Moredun Research Institute (MRI), Edinburgh. Here P. ovis mites were 
maintained on sheep that had had no previous exposure to acaricidal treatment. 
The mites have been in continuous culture without exposure to acaricide for at 
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least 10 years. Four samples were obtained from the MRI, Edinburgh for 
experimental work on 15/11/2017, 20/12/2017, 02/02/2018 and 17/03/2018. 
Samples of field outbreaks that did not appear to have responded to standard 
acaricidal treatment were collected from veterinary surgeries from across the UK or 
posted by the veterinarians.  Veterinarians or farmers with non-responding flocks 
contacted the study investigator through a network of veterinary contacts, and 
through contacts arranged by Zoetis Animal Health or Public Health England (Sian 
Mitchell).  Collection was pre-arranged and posted samples were sent by special 
delivery, ensuring mites were off-host for less than 24 h between the skin 
scrape/collection and being used in bioassays. In total, 12 field samples were 
collected for the trials, but only 6 contained sufficiently large numbers of mites to 
allow their use. Mite sample origin and treatment history are detailed in Appendix 
B and Appendix C.  
2.2.2 Bioassay development and Sampling (naïve and resistant) 
The bioassay used to test for resistance was developed from the methodology of 
Doherty et al. (2018). Sterile petri-dishes (90 mm diameter) were partially filled 
with 18ml of potato dextrose agar (agar 15g/L; dextrose 20g/L, potato extract 4g/L, 
Sigma-Aldrich Ltd). On solidification, a surface layer of 1ml 5% Sigma-Aldrich sterile-
filtered sheep serum and 1ml treatment solution was added. After adding mites to 
the centre of the petri-dish, the inner rim of the petri-dishes and lids were smeared 
with petroleum jelly and sealed with parafilm to ensure that the mites were 
contained. 
In the current study, initial bioassay trials using MRI samples were used to confirm 
lethal conditions in which to test P. ovis mortality rate. The initial concentrations 
tested were 500ng/ml, 1000 ng/ml and 2000 ng/ml respectively, using the 
aforementioned study by Doherty et al. (2018) as a guide for concentration 
effectiveness. Under the experimental conditions of the present study bioassay, 
2000ng/ml was found to be effective, resulting in 100% mortality in MRI naïve 
population samples under moxidectin treatment. Under the other MLs being 
assessed in this study for cross-resistance testing, the initial MRI samples did not 
30 
reach 100% mortality at the 72h time point used for analysis (See Chapter 2.2.3). 
This result of the 2000ng/ml precursor assays is reflected in the results of the MRI 
mortality rate during trial bioassays (Fig. 2.4). An additional concentration was 
added, and the experimental trials were run using 2000ng/ml and 4000ng/ml. 
Three MLs were used in the bioassays (Table 2.1), diluted in 100% ethanol to 
achieve the concentrations and lower concentrations used were abandoned for 
use in bioassay analysis due to the sample size required to test more than 2 
concentrations adequately.  
Negative control plates were made in an identical manner for each trial with 1ml 
absolute ethanol in place of the ML. Each concentration and ML treatment had 3 
identical repeat plates with 10 mites placed on each plate for each trial. Before 
being added to a plate, the mites were tested for a locomotory response using 
tactile stimulation. Only mites capable of a full appendage contraction within 5 
seconds of stimulation using 3 untreated paintbrush strokes across legs I and II (L 
and R lateral side) and the gnathosoma were added to plates. This ensured all mites 
used were alive and capable of movement before treatment exposure.  
Table 2.1. The macrocyclic lactone, trade name, therapeutic dose and 
manufacturer of the compounds used in bioassays are reported here. 
Field and control samples of infected skin and wool were inspected using a 
stereomicroscope (Leica S6E) and mites were transferred to plates using 
paintbrushes. Each treatment and concentration had specific brushes used for mite 
Macrocyclic lactone Treatment ML Source 
ivermectin 
Oramec Sheep Drench, 0.08% 
w/v (Oramec) 
moxidectin 
Cydectin 20mg/ml Long Acting 
(Zoetis Animal Health) 
doramectin 
Dectomax 10mg/ml (Elanco 
Animal Health) 
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transfer to prevent the contamination of individual organisms with other MLs or 
concentrations. After all mites were placed on the bioassay plates for a trial, the 
plates were sealed and incubated at 20oC and 80% r.h. Smith et al. (1999) showed 
that Psoroptes survival was reduced at relative humidities  below 75% r.h. and a 
study by Brimer et al.(1995) demonstrated that MLs remain stable and active in 
agar plates at 20 °C over the duration of bioassay trials.  
Appendix D details a letter sent by the study investigator through the study contact 
network, after receiving samples that were not appropriate for bioassay analysis. 
Pre-assay mite mortality occurred due to desiccation in many samples until 
sampling instructions had been communicated with Veterinary and Animal health 
suppliers. The letter details the optimum sampling method and outbreak sample 
format based on initial pre-assay trials. For a successful trial, bioassay materials 
needed to be set up before an outbreak sample arrived at the laboratory.  
Within the desiccation time-sensitive window of < 4 hours, the treatment solution, 
sheep serum and P. ovis mites were placed on each assay plate. Plates were then 
incubated at the optimal relative humidity and temperature. In large samples, with 
many containers, only a single container was used at one time and the remainder of 
the sample were kept incubated to prevent mite desiccation.  
Mortality counts were recorded for all bioassay plates at 24 h intervals for 120 h 
after initial setup. A mite was categorised as alive based on tactile stimulation and 
locomotory response, as described previously. Again, treatment specific treatment 
brushes were used to avoid cross-contamination of treatments/concentration and 
brushes were rinsed in 100% ethanol in-between tests. 
2.2.3 Statistics 
The outbreak trial and control trial results were entered into Excel. The plate 
number, drug, concentration and number of live P. ovis mites at each 24h interval 
were recorded.  The percentage mortality for each plate and the median 
percentage mortality for each treatment were calculated in both the outbreak and 
the control populations. Non-parametric statistics were used throughout as the 
data were not normally distributed, as confirmed using a Shapiro-Wilk W test (P 
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Value< 0.05). R statistical software and Statgraphics were used to analyse the data. 
The final significant differences in % mortality for the 2000ng/ml and 4000ng/ml 
concentration trials were calculated using StatGraphics Centurion 18 software 
(Statgraphics, 2018; R Core Team, 2013) by performing Mann-Whitney U tests. A P 
value of <0.05 was considered significant. 
Mortality comparison statistics were taken at 72h for comparison between the field 
and naïve MRI control samples. The 72h time point was used due to control tests 
showing that under the optimal humidity and temperature conditions used in this 
study, there were no significant difference in % mite mortality between field 
(outbreak) and naïve control (MRI) population samples at 72h when exposed to 
ethanol and sheep serum (nutrition) only (W=26.0, P Value> 0.05). Initial pre-assay 
testing demonstrated that using this time point ensured that both control and 
outbreak mite mortality rates were due to experimental treatment conditions 
rather than time subject to off-host conditions. 
2.3 RESULTS 
2.3.1- Response of populations to control treatment bioassay  
Ethanol controls: 
When exposed to ethanol only, mites from both outbreak and MRI samples showed 
low mortality which, as expected, gradually increased with time subject to off host 
conditions. At 72 h after initial exposure, there was no significant difference in the 
% mortality between the MRI or outbreak populations (W= 26.0, P Value> 0.05).  
 
2.3.2- Response of Field and Control P. ovis mite samples to macrocyclic 
lactone bioassay 
Appendix E details a summary table of statistical differences between % mortality 
responses at 72h in ML treated and untreated control samples for both outbreak 





At 72h post exposure to 4000 ng/ml of moxidectin, both the outbreak and the MRI 
samples had a median % mortality of 100% (Fig. 2.3). When contrasting the 
response of MRI bioassays (Fig. 2.1; Fig. 2.3) to that of outbreak bioassays (Fig. 2.2; 
Fig. 2.3), MRI sample responses to 4000ng/ml moxidectin exposure were all >80% 
mortality, whereas the response of seemingly tolerant outbreak samples varied 
across the range, with two samples <70% mortality at 72h. Study on the blood 
plasma concentration of moxidectin in treated sheep found that at 12h post-
treatment, blood plasma concentrations peak at a maximum of 20ng/ml. By these 
findings (Lloberas et al., 2013), after exposure to the 4000ng/ml bioassay in the 
current study, the mites were subject to a 200-fold increase in concentration 
relative to standard dosages of veterinary treatment in the field. 
Using the Mann Whitney-U test for significance analysis, in the outbreak samples, 
there were significant differences seen in % mortality response to Moxidectin 
4000ng/ml and the outbreak sample control mites exposed to ethanol and sheep 
serum nutrition only (W=0, P Value< 0.05).  
When exposed to a 2000 ng/ml concentration of moxidectin, the median % 
mortality in the field outbreak samples was half that of the MRI mite populations 
(Fig. 2.4). Insufficient outbreak data were obtained after outbreak moxidectin 
exposure at this concentration for statistical analysis. However, the results obtained 
(Fig. 2.1; Fig.2.2), imply considerable disparity between the median % mortalities of 
outbreak and MRI sample responses.  
In the MRI naïve mites, there were significant differences seen in % mortality 
response to Moxidectin 4000ng/ml and the control MRI mites exposed to ethanol 
and sheep serum nutrition only (W=0, P Value< 0.05). There were also significant 
differences in % mortality to MRI mites exposed to the lower 2000ng/ml 
concentration and MRI control mites exposed to ethanol and nutritional serum only 






After exposure to doramectin 4000 ng/ml treatment, the results also imply 
considerable disparity between the sample group responses (Fig. 2.1; Fig. 2.2). At 
72h, the MRI samples median % mortality is 100%, as opposed to the outbreak 
samples responses, with a median % mortality of 15% (Fig. 2.3).  Dissimilarity 
between responses of outbreak samples and the MRI samples is seen after 
exposure to 2000ng/ml doramectin also (Fig. 2.4). After 4000ng/ml exposure the 
difference in % median mortality between outbreak and MRI sample response was 
85% lower in the outbreak samples compared with that of the MRI naïve samples. 
After exposure to 2000ng/ml, the difference was a 40% lower median mortality in 
outbreak samples than in the MRI samples.   
In the outbreak samples, there were no significant differences seen between % 
mortality response to Doramectin 4000ng/ml and the response of outbreak sample 
mites exposed to ethanol and sheep serum nutrition only (W=9.5, P Value >0.05). 
There were insufficient outbreak data after exposure to 2000ng/ml Doramectin for 
statistical comparisons at this concentration between outbreak treated and control 
groups. 
In the MRI naïve mites, there were significant differences seen in % mortality 
response to Doramectin 4000ng/ml and the control MRI mites exposed to ethanol 
and sheep serum nutrition only (W= 0, P Value <0.05). There were also significant 
differences in % mortality to MRI mites exposed to the lower 2000ng/ml 
concentration and MRI control mites exposed to ethanol and nutritional serum only 
(W= 0, P Value <0.05).  
Obtaining a larger data set through larger outbreak P. ovis samples would allow for 
full statistical analysis of these differences. The study objectives would benefit from 
a larger sample size for increased statistical confidence and reduced margin of error 
when contrasting responses to MLs between non-responding samples and the 
naïve MRI samples. Larger samples would allow more data on multiple ML testing 
within a single outbreak sample and so an in-depth analysis of significant 
differences between ML responses could be performed. This could indicate 
differences in susceptibility levels to each ML within outbreak groups and provide 
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evidence towards investigating shared biochemical target sites between the MLs 




After exposure to 4000 ng/ml ivermectin, there were significant differences in the 
% mortality seen at 72h between the outbreak and MRI naive samples (W=15.0, P 
Value <0.05; Fig. 2.1; 2.2; 2.3). Treated and untreated MRI naïve samples also had a 
significant difference in % mortality at 4000ng/ml (W=0, P value<0.05) (Fig. 2.1). 
There was no significant difference between the treated and untreated MRI 
samples after exposure to the lower 2000ng/ml concentration of ivermectin 
treatment (W= 0, P Value >0.05).  
There were also no significant differences between the % mortality seen in the 
outbreak samples exposed to ivermectin at either concentration when compared 
with the outbreak sample control mites exposed to ethanol and sheep serum 
nutrition only (4000ng/ml: W=18.5, P Value >0.05;  2000ng/ml: W= 8.0,  P Value 







Fig. 2.1.  The percentage mortality of Psoroptes ovis obtained from the Moredun 
Research Institute and exposed for 72 h to agar and sheep serum plates, treated 
with ethanol (squares) or moxidectin, ivermectin or doramectin at 2000 ng/ml 




Fig. 2.2. The percentage mortality of Psoroptes ovis obtained from non-
responding outbreak samples and exposed for 72 h to agar and sheep serum 
plates, treated with ethanol (squares) or moxidectin, ivermectin or doramectin at 






Fig. 2.3. Median percentage mortality of Psoroptes ovis outbreak population 
samples and Moredun Research Institute naïve control population samples 
exposed to macrocyclic lactone treatments at 4000ng/ml. Macrocyclic lactones: 
moxidectin (M), doramectin (D), ivermectin (I) Untreated controls exposed to 









































Fig. 2.4. Median percentage mortality of Psoroptes ovis outbreak population 
samples and Moredun Research Institute naïve control population samples 
exposed to macrocyclic lactone treatments at 2000ng/ml.  Macrocyclic lactones: 
moxidectin (M), doramectin (D), ivermectin (I) Untreated controls exposed to 










































There were no significant differences found between the tolerant outbreak samples 
and ML naïve MRI samples when exposed to moxidectin or doramectin at 
4000ng/ml (Moxidectin: P Value >0.05) (Doramectin: P Value >0.05). This is 
arguably expected for moxidectin as it is known to be the most effective ML 
treatment against P. ovis and particularly effective in parasites showing resistance 
to avermectin treatments (Prichard et al., 2012). The mites were exposed to the 
highest laboratory concentration which is much higher than the concentrations that 
in-field P. ovis infections would be exposed to, through standard treatment dosage 
(See Chapter 2.3.2 “Moxidectin”). It appears that the moxidectin 2000ng/ml data 
also commensurate the findings of the Doherty et al. (2018) study discussed 
previously (See Chapter 1.3.2), in that outbreak samples appear to have a much 
lower mortality % than those of MRI samples exposed to the same treatment (Fig. 
2.4). A larger sample size would be necessary to explore the statistical validity of 
this phenomenon as with the doramectin exposure outbreak responses at the 
lower 2000ng/ml concentration (See Chapter 2.3.2 “Doramectin”). The higher 
concentration was preferred with the low sample sizes of the current study. As 
discussed, this was based on the limitations and impacts of the off-host 
environment on natural mortality and mite condition and sample sizes, seen under 
the pre-assay trials of the study methodology (See Chapter 2.2.2). 4000ng/ml was 
favoured in each individual bioassay in order to acquire sufficient data for analysis 
under the highest concentration.  
Surprisingly, despite a significant difference seen between treated and untreated 
outbreak samples when exposed to 4000ng/ml moxidectin, there is no significant 
difference between treated and untreated outbreak control sample response after 
exposure to 4000ng/ml doramectin. Paired with the evidence of a reduced 
response in outbreak samples to both moxidectin and doramectin 4000ng/ml in 
comparison to the % median mortality in MRI sample responses (Fig. 2.3), this data 
indicates that non-responding outbreak populations show a high level of resistance 
to doramectin and maintain the natural mortality rate under treatment with 
doramectin-based ML compounds. The results of the % mortality after ivermectin 
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exposure insinuate that it was the least effective ML used in this study based on the 
% mortality response of both outbreak and MRI P. ovis samples. However, the MRI 
samples show a consistently high mortality to both ivermectin concentrations (Fig. 
2.1).  There was a significant difference between the MRI samples treated with 
4000ng/ml and the untreated mites, but this is not the case at 2000ng/ml, 
suggesting that the threshold for Ivermectin to be effective on P. ovis responsive 
mortality requires a very high concentration. The significant difference seen 
between treated outbreak samples and MRI naïve samples after 4000ng/ml 
ivermectin exposure is reflected visually in the figures (Fig. 2.1; Fig. 2.2; Fig. 2.3; Fig. 
2.4) and represented in Appendix E. 
2.4  DISCUSSION 
The results of this study must be interpreted with care. Outbreak populations come 
from farms that reported that their infestation of scab had not responded to 
treatment. But lack of response may be due to a variety of factors, one of which 
may be resistance, but another may simply be improper application of the acaricide 
used. Hence, it should not be surprising that some of the outbreak populations did 
appear to be susceptible to the ML against which they were tested. For example, in 
the trials with moxidectin at a concentration of 4000 ng/ml most of the mites 
tested appeared to be susceptible, suggesting that no resistance was present. 
However, upon closer inspection it can be seen that 3 of the outbreak samples 
exhibited lower % mortality than the MRI control samples (Fig.2.1; Fig. 2.2), while 
the others did not. Differing responses may also be attributed to the fact that each 
non-responding outbreak sample had a different previous treatment history. 
Furthermore, the study was only able to obtain mites from a relatively small 
number of outbreak populations, and in most of these cases only small numbers of 
mites could be obtained from the wool and scab samples submitted.  
The concentrations of the MLs used in the bioassays are significantly higher than 
the plasma concentrations that a mite would be expected to encounter in serum on 
a sheep and higher that those used by Doherty et al. (2018). These high 
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concentrations were selected to maximise the challenge presented to each exposed 
mite and give confidence to the conclusion that mites were or were not resistant to 
the compound. Whilst the mechanism of resistance are not currently known, the 
MRI naïve samples % mortalities after treatment compared with that of the less 
susceptible outbreak samples, demonstrated a clear difference in response. The 
phenomena that some outbreak samples proved less susceptible to the lower 
2000ng/ml moxidectin and doramectin concentrations than the MRI samples (Fig. 
2.4), whilst still showing a high % median mortality to the 4000ng/ml 
concentrations (Fig. 2.3) may indicate that there is some biochemical level of 
mortality threshold and partial resistance in unresponsive cases of sheep scab. 
Some cases of ML resistance in other parasitic species are conferred through a 
lower binding affinity to ML treatments at glutamate-gated chloride channel 
subunits (McCavera et al., 2007). In the case of a resistance mechanism that is 
related to a lowered binding affinity, it is possible that a higher concentration would 
cause enough instances of treatment chemical interaction with the action site, that 
the chances of an active chemical bond forming are higher. 
Another example is that of resistance to moxidectin and ivermectin conferred 
through genes coding P-glycoprotein expression seen in strains of Caenorhabditis 
elegans (Bygarski et al., 2014), which as previously discussed (See Chapter 1.3.2) 
also confers resistance in H. contortus. Therefore, the results in this study may also 
indicate that the higher treatment concentrations can overcome this tolerance in P. 
ovis if resistance is conferred by the same biochemical target mechanisms. 
However, the restrictions of safe concentration levels in veterinary treatment 
would impede solutions to this that use concentration levels alone. An increased 
understanding in the biochemical target sites of resistance could guide the 
development of novel treatments with a different mechanism of action and 
biochemical interaction.  
The general pattern of mortality seen in this study strongly implies there is 
resistance to all 3 common ML treatments in many of the non-responding outbreak 
populations, when their mortality is compared with the much higher levels of 
mortality seen in the naïve control samples obtained from the MRI populations. 
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Where outbreak samples did show susceptibility to the test MLs it suggests that 
environmental factors, such as ineffective or inappropriate application technique or 
repeated infection, particularly in the case of ivermectin where there is no residual 
activity, are likely to be responsible for the persistent scab. P.  ovis have been 
reported as surviving for up to 38 days off host, although survival is strongly 
seasonal (Babcock and Black, 1933). Mites have been shown to retain infectivity off 
host for at least 15 days. Adult females survive longer than males and all mites 
survive longer off-host at cooler temperatures. Eggs are also viable for a week in an 
off-host environment (Shilston, 1915; O’Brien et al., 1994). Therefore, all 
equipment, land and territory instalments e.g. fencing/walls that enclose an area 
with infected individuals, must be considered as a re-infection source and the flock 
must be quarantined. There are also accounts of under-dosing or weight 
measurement errors, resulting in ineffective doses of ML being administered as 
treatment (O’Brien, 1999). Above are some examples of the more common reasons 
that could result in a case of false suspected resistance.  
During the study, the most common ML for which resistance was suspected was 
moxidectin. In the previous study assessing resistance in P. ovis, only moxidectin 
was considered and outbreak populations showed 20%-30% mortality at 72h after 
exposure to a 2000ng/ml concentration of moxidectin treatment (Doherty et al., 
2018). In this study, the median mortality in outbreak populations was 50% at 72 h 
after exposure to the same concentration of moxidectin. Given the sample sizes the 
difference in mortality between the studies is not unexpected, but additional slight 
differences between the methodologies used in the studies might have also 
contributed to the difference. Mites were exposed to treatment directly through a 
surface layer of treatment plate solution in the current study, rather than indirect 
uptake through the treatment mix within plate agar. The method of treatment 
uptake has not been conclusively defined. However, whether ingested through the 
gnathosoma (feeding organs) of the mites or absorbed through the cuticle surface 
directly, direct treatment exposure would expectedly result in a higher absorption, 
thus higher saturation or ingestion of the treatment chemical.   
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There are many other factors that may affect treatment efficacy in addition to 
resistance that should be considered. It was thought that contributing factors which 
impact sheep-scab treatment response in the field may include the age and sex of 
the infected sheep, however, upon investigation, there were no statistically 
significant differences between infection prevalence and age or sex of infected 
individuals (Tasawar et al., 2007). Although these compounds are highly stable and 
have high lipophilicity (Campbell and Benz, 1984; Prichard et al., 2012; Vercruysse 
et al., 2018) subtle variations in their formulation may affect their activity. It has 
been suggested that treatment efficacies of the same ML may vary between 
different products; it has been argued for example that generic products may be 
less effective than branded products and that the method of administration may 
impact the pharmokinetics and efficacy of some ML treatments (Eraslan et al., 
2010; Toscan et al., 2012).   
Nevertheless, in a trial, 22 cattle infected with P. bovis were allocated at random 
into groups. Two injectable brands of ivermectin were administered at an 
appropriate dosage for individual cattle weight. The cattle were subject to the 
same environmental conditions and the groups were kept separate to avoid cross-
contamination or parasite transmission (Genchi et al., 2008). No difference was 
found in efficacy or pharmacokinetic profile between two separate brands of 
ivermectin (Genchi et al., 2008; Hamdullah et al., 2015). Further study with more 
samples and experimental focus on treatment history would be required to 
quantify the effect of these factors on P. ovis mortality, including specific treatment 
brand and administration method. 
The Insecticide Resistance Action Committee (syn IRAC) classifies acaricide modes 
of action into categories based on the physiological functions they target. These 
include respiratory, nervous system, growth and midgut targets. Avermectins and 
milbemycins are classified into the glutamate-gated chloride channel allosteric 
modulators. Twenty-five groups of known acaricide targets have been defined, with 
an additional group of 4 drugs of which the mode of action is unknown (IRAC, 
2016). The Doherty et al. (2018) study was the first to demonstrate resistance of P. 
ovis to moxidectin, and so the physiochemical mechanisms of resistance have not 
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yet been identified. Nevertheless, the similar mode of action of macrocyclic 
lactones would be expected to confer cross-resistance across the class 
(Wolstenholme, 2012). The response of outbreak samples to doramectin and 
ivermectin trials in the current study provides further evidence of growing 
resistance in UK field populations across the macrocyclic lactone class of 
compounds. Percentage mortality responses of outbreak samples exposed to 
4000ng/ml ivermectin and those exposed to 4000ng/ml doramectin were not 
significantly different from controls from the same outbreak samples exposed to 
ethanol-only which, as discussed (See Chapter 2.3.2 “Results summary”), indicates 
that non-responding outbreak populations demonstrate a high level of resistance to 
both compounds and maintained a natural mortality rate that mirrored the 





Livestock ectoparasites are ubiquitous and it is usually extremely difficult or 
impossible to fully eradicate non-isolated populations (Wall, 2007). Management at 
a local level, and consistent integrated approaches, designed to maintain low 
regional prevalence, are usually necessary to minimise the economic and welfare 
consequences from these parasite species. In the case of P. ovis mites, the co-
evolution and symbiotic association between the mites and their wild hosts, seen 
largely as relatively benign ear forms, has been disrupted in the last few thousand 
years, by the artificial selection of more highly productive sheep breeds in domestic 
farming and the introduction of an array of transmission factors associated with 
intensive animal husbandry (Stevens et al., 2006). For example, a study by Rose et 
al. (2011), analysed sheep movement and ranging on common land finding that in 
Wales, 99% of a flock’s range was shared with 1 or more other farms. This study 
identified common grazing as a significant transmission and risk factor for 
reoccurring scab outbreaks. 
The evidence presented in this study strongly suggests that resistance to multiple 
MLs is present in UK based outbreaks of P. ovis, posing increased financial and 
welfare threats for the veterinary and agricultural community. At present, this 
appears to be largely confined to Wales and the Welsh-borders.  If resistance is able 
to spread, scab prevalence in Britain would be expected to increase over the next 
decades (Doherty et al., 2018).   
Insecticide resistance: 
The development of resistance to insecticides is influenced by a combination of 
factors, from genetic mechanisms underlying treatment interaction, through to the 
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frequency, dose and method of acaricide application. Studies have suggested that 
most resistant alleles are recessive and disadvantageous in the absence of 
endectocide; in vitro experiments have shown reduced reproductive ability, thus 
lower reproductive output in individuals with resistant alleles (Georghiou and 
Taylor, 1977). To more efficiently manage and prevent accumulation of resistance 
gene selection, the IRAC advocate seasonal rotations of acaricides/insecticides with 
different modes of action and target areas of parasite physiology (IRAC, 2016). In 
practice however, in the case of P. ovis, the lack of alternatives to MLs makes this 
difficult. Study into minimising selection for resistance to ivermectin, moxidectin 
and another ML, abamectin (an insecticide used for ovine helminth infections), 
found that even when rotating ML treatments and combining different drugs for 
treatment, it is unlikely to delay selection for ML resistance. The results of the study 
by Dobson et al. (2001) highlighted the importance of monitoring ML and drug 
combination efficacy through post-treatment parasite screening. The authors also 
concluded the importance of reducing ML reliance through avoiding regular annual 
use and treating conditions with lower efficacy drugs where appropriate.  
 
Mechanisms of resistance and cross resistance:  
Understanding mechanisms of ML resistance in Psoroptes mites is an important 
next research step, as it may be able to contribute to the development of novel 
working treatments, or biochemical modifications to current products. As 
discussed, the strongylid ovine parasite, H. contortus, has also shown resistance to 
MLs, which has been associated with the over-expression of P-glycoproteins 
(Molento et al., 1999). Understanding resistance on a molecular level is essential to 
allow the identification of the site of action between the resistant parasite and the 
treatment chemical structure. This understanding can then guide the development 
of working treatment solutions. Molecular research into the changes in genome 
which confer resistance allow for biomarker recognition and the creation of early, 
asymptomatic diagnostic and treatment methods.  Molecular research of resistant 
H. contortus strains, found polymorphism within the alleles, glc-5 and lgc-37. Glc-5 
is a glutamate-gated Cl− channel subunit and Igc-3 is a subunit of the GABA-gated 
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chloride channel, both of which are targeted by MLs. The specific nucleotide change 
responsible is yet to be discovered, however, the alleles associated with ML 
resistance in vitro, were seen in vivo also to be related to adult feeding and larval 
locomotion (Beech et al., 2010). An increase in resistant allele frequency in H. 
contortus populations, under treatment exposure, requires a selective pressure that 
favours a genetic advantage in the surviving members (Blackhall et al., 1998). The 
information known for ML resistance mechanisms in other parasitic organisms may 
indicate target sites that would require molecular analysis and investigation in P. 
ovis mites which appear unsusceptible to treatment.   
Perhaps molecular evidence on drug resistance in other arthropod Acari would 
provide an initial framework to guide research, given the closer taxonomic 
relatedness to P. ovis than that of H. contortus. For example, the important crop 
pest – the two-spotted spider mite, Tetranychus urticae, exhibits insensitivity to 
acaricide treatments. As with P. ovis the rapid life-cycle and high rate of 
reproduction of T. urticae facilitates the rapid development of resistance under 
acaricidal selection pressure (Van Leeuwen et al., 2010). It is likely that P. ovis will 
show varying levels of resistance between populations and host variants. A study of 
15 genetic variants of T. urticae, found differences in the levels of sensitivity to 8 
acaricides in toxicity assays. Resistant strains were classified by a <50% mortality 
after exposure or recorded as highly resistant if mortality remained low at 500% of 
the discriminating dose. Two T. urticae variants demonstrating high resistance 
levels to acaricides were also found to resist cyflumetofen, a chemical that had not 
been used in the relevant regions of Europe before the study and so was not a 
compound the mites had been knowingly exposed to previously. This further 
implies the importance of understanding shared target mechanisms of resistance in 
parasite-treatment interaction. Other variants showed a wider spread of resistance 
to more common treatments (Khajehali et al., 2011).  
The demonstration of cross-resistance to compounds related to or chemically 
similar to the treatments organisms are insensitive to, has also been observed in 
Drosophila through a mutation resulting in gene upregulation. Insertions of 
transposable elements in the leader RNA sequence, 5’UTR regions, are well-
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documented and transposition in the Cyp61 gene of Drosophila is particularly 
noteworthy in regard to cross-resistance. The enzyme metabolises neonicotinoids 
and DDT, thus a mutation resulting in upregulation of the encoding gene elicits 
cross-resistance to both compound classes (Daborn et al., 2002; Schmidt et al., 
2010). In the Southern cattle tick, Rhipicephalus microplus, an economically 
important agricultural ectoparasite, resistance to MLs has been reported to result 
from an insensitivity of GABA or chloride channels. Altered acaricide sensitivity at 
biological target sites by genetic point mutations, cause a significant proportion of 
the cases of resistance development.  Resistance to the ML, abamectin, has been 
shown to be usually autosomal, recessive, and determined by multiple gene 
inheritance. Resistance is conferred through a decrease in binding sites, especially 
at the GABA alpha subunits (cys-loop ligand-gated ion channels) of the GABA A 
receptor (Clark et al., 1991; Clark et al., 1995; Barnard et al., 1998).  
There are a group of known mutations in Acetylcholinesterase genes (AchE or ‘Ace’ 
genes) which provide resistance mechanisms to organophosphates and other 
insecticides in other species of ectoparasitic arthropods, including some species of 
mite and ticks. The molecular characterisation of these can be complicated because 
the number of AchE genes varies between arthropod species (Temeyer et al., 2004; 
Grbić et al., 2011; Feyereisen et al., 2015). The ESTHER database has more than 12 
records of sites in different organisms and a collection of polymorphisms that have 
mutant AchE genes, causing tolerance to insecticides (Lenfant et al., 2013). 
Mutations in the GABA receptor gene coding region have been discovered in 27 
arthropod species (Feyereisen et al., 2015). The GABA-gated chloride channel 
subunit targeted by the insecticides, cyclodiene and phenylpyrazole, is encoded by 
the Rdl gene. A single-point mutation in this gene coding region, resulting in an 
amino acid replacement of Ala301 to Ser, confers cyclodiene resistance (Remnant et 
al., 2013). Widespread use of cyclodiene during the 1980s, evoked insensitivity to 
the treatment in 62% of species that had demonstrated insecticide resistance 
(Georghiou, 1986).  
As previously mentioned (See Chapter 1.3.3), developments into a vaccine have 
only proven partially protective against P. ovis. The MRI division working on a 
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vaccine have published the first draft genome of the P. ovis mite (Burgess et al., 
2018). This development in molecular understanding may act as a valuable resource 
for genetic understanding and as a comparison genome between samples which 
respond and samples which appear unresponsive to treatment, to find any point 
mutations in P. ovis which confer ML resistance. Presently, there has been further 
development in molecular understanding of acaricide insensitivity in T. urticae than 
in P. ovis, and as mentioned, understanding resistance target sites in closely related 
organisms is likely a fundamental step in finding novel control methods for resistant 
P. ovis.
Homologues of RNAi transcript sequences in the T. urticae genome have recently 
been identified and these have led to successful gene silencing attempts and a 
substantial reduction in transcript levels of three target sequences which encode 
the sheep scab allergen protein, Pso o 2, in P. ovis (Marr et al., 2018). This further 
emphasises the importance of comprehensive molecular analysis of resistance 
mechanisms and shared chemical characteristics between treatment compounds. 
As well as using shared biochemical features between the physiological interactions 
with compounds in different species that appear insensitive to same insecticides, as 
a reference for investigation into resistance mechanisms.  
Current state of Psoroptes ovis management in the United Kingdom: 
It can be argued that the current UK approach to P. ovis control is unreliable and 
unsustainable. Persistent outbreaks arise from inappropriate or ineffective 
treatment, inconsistency of treatment between in-contact farms and/or poor 
biosecurity leading to repeated reinfection (Rose et al., 2011). Furthermore, the 
absence of nationwide surveillance means that inadequate data are available to 
track scab incidence, since data collection within academic research projects results 
in infrequent and out-of-date prevalence estimates. Following reintroduction of the 
disease, the lack of coherent national management allowed scab to spread and 
become more prevalent. The increase in prevalence was also helped by repeated 
infection particularly from feral sheep on common land acting as reservoirs 
(Roberts and Meleney, 1971), the lower residual activity of organophosphates 
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compared to organochlorines, in addition to the fact that some mites were able to 
escape dip through inhabiting “cryptic (or latent) sites”. For example, P. ovis 
infections in ear canals where dip has been shown to be unable to penetrate 
(Kirkwood and Quick, 1978). These factors all contributed to the inability to re-
eradicate scab (Bates, 1991; Sargison and Busin, 2014).  In addition, considerable 
misunderstanding within the sheep farming community on the appropriate types 
and timing of treatment has been demonstrated (Bisdorff and Wall, 2007). The 
latter survey showed that prophylaxis treatment for scab was often given during 
summer months, which is ineffective for protection because the peak outbreak 
period is in winter and inappropriate insecticide were used, such as the insect 
growth regulator cyromazine (Bisdorff and Wall, 2007). Now, with the development 
of resistance to macrocyclic lactones, the management of scab is likely to be 
considerably more difficult and the range of potentially useful acaricides is now 
much more limited. Paradoxically, the presence of resistance in Psoroptes to MLs 
may help slow the development of resistance to these compounds in GI nematodes, 
since it should eventually reduce their use against scab, and the unnecessary 
concomitant exposure of worms. As previously discussed (See Chapter 1.3.1), 
treatment for ovine worm infections and other ovine diseases can inadvertently 
expose undetected sub-clinical scab to low-level ML doses, provoking resistant gene 
selection (Coles, 1998).  
Five of the six outbreak samples of the working trials of this project, contained a 
large enough number of P. ovis mites to allow tests against more than one ML in a 
single bioassay trial. Of these five, three demonstrated resistance to more than one 
ML. A thorough, replicated assay with much larger sample sizes from non-
responding P. ovis outbreaks would be necessary to demonstrate cross-resistance 
conclusively.  Obtaining such large numbers of mites from clinical cases, however, is 
difficult.   
 
Future directions to manage resistant scab: 
To date, as seen in this study, most reports of resistant outbreaks are located in 
Wales and the Welsh borders (Doherty et al., 2018). In terms of the future 
52  
 
management of scab in the UK, analysis by French and Wall (1999) indicated clear 
associations between changes in government scab management policy and scab 
prevalence, demonstrating the impact and importance of central government-led 
policy in national management. The analysis also identified local space-time 
clustering, with higher levels of incidence within a five-month time span in farms in 
close proximity to each other, demonstrating the importance of contact between 
infected flocks in scab transmission. This is supported by data showing that scab risk 
is highest on farms that use regional common grazing (Rose et al., 2011; Chivers et 
al., 2018). This is an important consideration for policy formation looking at 
minimising the spread of resistant outbreaks of P. ovis. Other considerations that 
need to be included in the context of scab management include the behaviour of 
farmers and the economic justification and incentives supporting prophylactic 
treatment. A game-theory model analysing current national scab trends showed 
that prophylactic treatment is only economically favourable in upland farms where 
scab prevalence is highest. The model shows that prophylactic treatment would 
need government subsidy in lower-risk areas for high levels of compliance through 
being cost effective for farmers (Nixon et al., 2018). In the future, it may be possible 
to slow the spread of resistant genes across the country, although this will be 
difficult.  Genetic biomarkers for resistance would be useful to help identify 
resistant populations quickly and effectively, particularly at the asymptomatic 
stages of infection.   
Recently, ELISA tests (enzyme-linked immunosorbent assays) have been developed 
and marketed, that are able to detect sub-clinical scab for rapid diagnosis.  The first 
assay was developed in 2001, modified from a previous assay used for P. bovis 
detection (as described by Lonneux et al., 1996), but it has been continuously 
improved since this time. A subsequent version of the ELISA had a 96.5% specificity 
and 93.7% sensitivity in clinically presenting sheep with moderate levels of 
detection 2 weeks before clinical signs (Ochs et al., 2001). This assay has been 
further refined to give a sensitivity of 98.2% and specificity of 96.5% (pers comm. 
S.Burgess, MRI).  Application and further development of the ELISA assay may 
represent a major advance in scab management, allowing for sub-clinical detection 
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and providing a cheaper, more rapid and more reliable method than physical mite 
detection, since the latter requires the presence of clinical signs to provoke 
veterinary investigation (Whitesides, 2006; Busin et al., 2015). Perhaps the most 
promising development of these technologies is the transfer of lab-based ELISA to 
paper (P-ELISA). Whilst this method has significant potential, the sensitivity is still 
considerably lower than that of lab-based assays. The acute phase proteins, 
haptoglobin (Hp) and serum amyloid (SAA) have been identified through serological 
assay as conclusive biomarkers for sheep scab (Wells et al., 2013). The advantage of 
a further refined P-ELISA with accurate in-field specificity and multi-antigen 
sensitivity, detecting the acute-phase proteins and scab associated antibodies such 
as IgG, is that it would allow for pre-clinical signs detection, accessible testing and 
the removal of a significant proportion of the associated costs of clinical diagnosis. 
Regulated periodic screening using commercially available P-ELISA testing may be 
able to detect sub-clinical scab in time to prevent spread (Busin et al., 2015). This 
could lower mass exposure and the over-use of MLs which contribute to resistance 
development and associated selection pressures favouring resistant alleles (Bisdorff 
and Wall, 2008). 
To counteract the spread of resistance, co-operation between farmers including co-
ordination of treatment, and novel approaches to diagnosis and treatment are 
required (Scott et al., 2007). This is likely to require the development and 
implementation of integrated approaches which give significant attention to 
maximising animal welfare and minimising resistance development. Given the lack 
of compliance and co-operation often evident in farming communities (Rose et al., 
2011; Nixon et al,. 2017), this may require government intervention. A centrally-
managed, cooperative system with consistent monitoring may be the only way to 
keep prevalence below levels that are commensurate with good animal welfare in 
the UK.  
The evidence presented in the current study implies a shared target mechanism in 
P. ovis which confers resistance across all three MLs tested. This provides important 
knowledge when combined with recent genetic developments in sequencing a draft 
P. ovis genome and in silencing P. ovis transcripts (Burgess et al., 2018; Marr et al., 
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2018). Further investigation guided by the knowledge of these recent findings, is 
paramount in allowing for considerably more optimism in the wake of approaching 
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Appendix A: Schematic representation of the proposed mode of action for the 
macrocyclic lactone endectocides: Based on Wolstenholme and A.T. Rogers 
(2002).
Macrocyclic lactone administered 
Altered ability for 
nutrient ingestion 
Altered movement ability 
towards optimum site 
Psoroptes ovis  
Paralysis and Death 
Cellular hyper-polarisation 
Binds to glutamate-gated chloride 
channels (GluCl) in nerve and muscular 
cells 
Increased permeability to chloride ions 
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Appendix B. A summary table of the acquisition date, origin and previous treatment history (treatment date, dose, active ingredient and mode 







Origin Name Drug Treatment History 
1 N Oswestry Too few active mites present for trial 
2 N Camalas farm vets Too few active mites present for trial 
3 Y Camalas farm vets 
20mg/ml moxidectin 2% LA, ivermectin 
200mcg/kg- Bimectin (1% ivermectin) 
4 Y Camalas farm vets 
02/10/17 Cydectin 2% LA (moxidectin 20mg/ml) 
7th & 14th 12/17 Bimectin 1% w/v (ivermectin - dosage 200mcg/kg) 
03/01/18 Sheep dipped 
5 N Honddu Vets, Brecon Too few active mites present for trial 
6 N Honddu Vets, Brecon 13/11/17- moxidectin 2% - i/m 
7 N 
Leigherton Farm (Bought 
from a farm at the Welsh 
Border: Monmouthshire) 
23/11/17- 2.5ml Cydectin 2% (moxidectin) 
5ml Monepantel (Zolvix- antihelmintic drug). 
8 N Camarthen Vets 
22/11/17- 20mg/ml Cydectin LA (moxidectin) 
06/12/17- Dectomax 10mg/ml - i/m  (doramectin) 
9 Y St James Swansea 19/11/17 & 10/12/17  Zermex LA (2%  moxidectin) 
10 Y Shepton Farm Vets 15/01/18- Cydetin LA (moxidectin), ivermectin. 
11 Y Penbode Farm Vets 12/17- Molemec (1% ivermectin) 





Appendix C: Psoroptes ovis spp. UK field samples distribution collected for bioassay treatment response analysis 
 Sample locations with enough mites suitable for bioassay analysis 
            Sample locations without enough mites suitable for bioassay analysis 
 
Appendix D: Letter written by the study investigator detailing instructions on 
collecting and sending samples of mites from non-responding outbreaks in order to 
maximise the likelihood of a successful bioassay analysis. 
 
Dear Veterinary Groups/Animal Organisations, 
Please find enclosed a clarification of the best method of delivering Psoroptes ovis 
samples that do not appear to respond to Macrocyclic lactones, in order for them to 
be trialled successfully. Please forward this letter to any farms vets who may also 
find it relevant.  
Upon suspected resistance, please notify me directly which day you are collecting 
the scrape/sample and the expected arrival day (before sending or whilst in transit). 
This gives me time to prepare the necessary test plates before sample arrival and 
alongside other bioassay analyses. The process is time-sensitive to ensure mite 
condition upon assay trial. 
 
Please detail any history of treatment you have for the duration that mites may have 
been present. E.g- If the sheep was treated at market a month before, which MLs, 
origin of sale etc. Please let me know which ML(s) the mites are not responding to 
when notifying that a sample has been sent/is being collected so I know which tests 
take priority and can have the appropriate treatments measured and ready 
beforehand. 
 
Please send the package by special delivery for next morning/afternoon arrival as 
soon as possible after the scrape. This is to ensure the mites are not compromised 
from time spent off-host. 
 
Please ensure a stamp/written sign of the parcel origin, ie- the veterinary group or 
sender name is on the envelope so that I know exactly which suspected case the 
mites are from as soon as it arrives. 
 
Please place scrapes inside plastic pots (with cello tape around all sealed edges) or 
in freezer bags (with cello tape across edge) to ensure no escaping mites. 
 
Deliveries sent on Sunday-Thursday Please address in the following format: 
Professor Richard Wall 
FAO C.S-Osborne 
Bristol University 
Life Sciences Building 
24, Tyndall Avenue 
Bristol, BS8 1TQ 
 
 







Contact details: XXX….XXXX….XXXX 
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Skin scrapes at the scab site are far more effective than wool- I cannot emphasise 
this enough in terms of successful/useable samples. P. ovis will only reside in wool 
incidentally and are always present at skin level at the site of scab/dermatitis. 
Unless there are hundreds of highly active mites, the wool will have too few mites to 
find before the sample becomes too desiccated during microscopy. In active 
infestations the mites will crawl out of the wool but this is very rare and they are 









Summary table detailing all ML treated outbreak and ML treated MRI naïve samples against outbreak untreated controls and MRI untreated 
controls. 
Treatment ML (ML) Concentration Group 1 samples Group 2 samples 
Significant 
difference 
between Group 1 
and Group 2 




nutrition sheep serum 0 control outbreak control naïve MRI N 
W = 48.5   P-value = 0.428854 
moxidectin M 4000 Treated outbreak  Treated naïve MRI N W=12.5 P-value= 0.699009 
moxidectin M 4000 Treated outbreak Untreated outbreak Y W = 0   P-value = 0.000782803 
moxidectin M 4000 Treated naïve MRI Untreated naïve MRI Y W = 0   P-value = 0.0497457 
moxidectin M 2000 Treated outbreak  Treated naïve MRI N/A Insufficient data 
moxidectin M 2000 Treated outbreak Untreated outbreak N/A Insufficient data 
moxidectin M 2000 Treated naïve MRI Untreated naïve MRI Y W = 0   P-value = 0.0497457 
doramectin D 4000 Treated outbreak  Treated naïve MRI N W=6.0 P-value=0.106583 
doramectin D 4000 Treated outbreak Untreated outbreak N W = 9.5   P-value = 1.0 
doramectin D 4000 Treated naïve MRI Untreated naïve MRI Y W = 0   P-value = 0.0435964 
doramectin D 2000 Treated outbreak  Treated naïve MRI N/A Insufficient data 
doramectin D 2000 Treated outbreak Untreated outbreak N/A Insufficient data 
doramectin D 2000 Treated naïve MRI Untreated naïve MRI Y W = 0   P-value = 0.0435964 
ivermectin Iv 4000 Treated outbreak  Treated naïve MRI Y W=15.0 P-value=0.034661 
ivermectin Iv 4000 Treated outbreak Untreated outbreak N W = 18.5   P-value = 0.625094 
ivermectin Iv 4000 Treated naïve MRI Untreated naïve MRI Y W = 0   P-value = 0.0497457 
ivermectin Iv 2000 Treated outbreak  Treated naïve MRI N W= 4.0 P-value=0.245277 
ivermectin Iv 2000 Treated outbreak Untreated outbreak N W= 8.0 P-value=0.901379 
ivermectin Iv 2000 Treated naïve MRI Untreated naïve MRI N W = 0   P-value = 0.105192 
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